Logo Image
News
Media
Medical World NewsPodcastsVideosInsightsPeer ExchangeMedia DayNews NetworkRoundtablesShorts
Conference
Conference CoverageConference Listing
Publication
More
CME/CE
Partners
Resources
Interactive ToolsSpecial ProjectsSponsored
Contribute
Case StudiesWriters and Mentors
Clinical Forum Insights

Subscribe

  • News
  • Media
  • Conference
  • Publication
  • CME/CE
  • Partners
  • Resources
  • Contribute
  • Subscribe
  • Clinical Forum Insights
  • Antimicrobial Stewardship
  • Blood-Borne Diseases
    • Ebola
    • HCV / Hepatitis
  • Coronavirus / COVID
  • Food Borne Infection / Food Safety
    • E. Coli
    • Food Safety
    • Listeria
    • Salmonella
  • Fungal Infections
    • Candida auris
  • Gastrointestinal Infections
    • C. Difficile
    • H. Pylori
    • Norovirus
  • Healthcare Associated Infections (HAI)
  • Prevention
    • Antibiotics
    • Immunizations
    • Vaccines
  • Respiratory Infections
    • Community-Acquired Pneumonia
    • Measles
    • Influenza
  • Sexually Transmitted Diseases
    • HIV / AIDS
    • HPV
    • HSV
    • PrEP
  • Skin & Soft Tissue Diseases
    • MRSA
  • Zoonotic & Vector-Borne Diseases
    • Lyme Disease
    • ZIKA
Spotlight -
Vaccines in America|
Antibiotics Deconstructed|
Bench to Bedside With SIDP|
Antimicrobial Stewardship|
Hepatitis
Advertisement

Kirk Hevener, PharmD, PhD

Advertisement

Articles by Kirk Hevener, PharmD, PhD

Study Shows Sulfonamide Antibacterials Capable of Reversing Azole Resistance in Candida albicans

ByKirk Hevener, PharmD, PhD
June 28th 2018

Preliminary studies provide convincing evidence for the synergistic use of sulfonamide agents with azole antifungals.

Advertisement

Latest Updated Articles

  • Study Shows Sulfonamide Antibacterials Capable of Reversing Azole Resistance in Candida albicans
    Study Shows Sulfonamide Antibacterials Capable of Reversing Azole Resistance in Candida albicans

    June 28th 2018



Advertisement
Advertisement

Trending on Contagion Live

1

Lenacapavir and the Future of HIV Prevention: PURPOSE Trials, Long-Acting PrEP, and What Comes Next

2

Initiatives Look to Strengthen Vaccine Policy and Governance in US

3

Hackensack Meridian Health Joins Phase 3 Trial of Pfizer’s Investigational C difficile Vaccine

4

Infectious Disease Regulatory Watch: June Highlights

5

European Commission Approves Glecaprevir/Pibrentasvir for Hepatitis C

  • About Us
  • Advertise
  • Editorial
  • Contact Us
  • Do Not Sell My Information
  • Privacy
  • Terms & Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

  • Contagion Live
  • CGT Live
  • Neurology Live
  • HCP Live
  • Oncology Live
  • Contemporary Pediatrics
  • Contemporary OBGYN
  • Urology Times
  • The Educated Patient
  • Patient Care Online
HCP Live Network
Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us